Imipramine Interactions

Tricyclic antidepressants may potentiate the effects of epinephrine.

Source: NLP:adrenalin (epinephrine)

Methylphenidate may inhibit the metabolism of imipramine. Downward dose adjustments may be required and plasma drug concentration should be monitored.

Source: NLP:dexmethylphenidate hydrochloride

May increase receptor sensitivity and enhance antidepressant activity; transient cardiac arrhythmias have been observed. Thyroid hormone activity may also be enhanced.

Source: NLP:liothyronine sodium

Co-administration can cause severe, prolonged hypertension. Monitor for hypertension if norepinephrine bitartrate cannot be avoided.

Source: NLP:norepinephrine bitartrate

Steady state plasma concentrations of imipramine can increase by approximately 30% when coadministered with alprazolam up to 4 mg/day. Clinical significance unknown.

Source: NLP:alprazolam

CYP2D6 substrate antidepressant. Bupropion inhibits CYP2D6, increasing imipramine exposure. Dose reduction may be necessary.

Source: NLP:bupropion hcl er (xl)

CYP2D6-metabolized antidepressant. Bupropion inhibits CYP2D6 and can increase imipramine concentrations. Consider dose reduction.

Source: NLP:bupropion hydrochloride

CYP2C19 substrate; diazepam may interfere with its metabolism, leading to potential drug-drug interaction.

Source: NLP:diazepam

Concomitant use may potentiate the cardiovascular effects of dopamine, including hypertension.

Source: NLP:dopamine hydrochloride

Tricyclic antidepressant that may potentiate the effects of epinephrine.

Source: NLP:adrenalin(r)

Methylphenidate may inhibit metabolism of this tricyclic drug. Downward dose adjustments may be required and plasma concentrations should be monitored.

Source: NLP:methylphenidate

Smoking cessation with nicotine replacement may require dose decrease due to deinduction of hepatic enzymes.

Source: NLP:nicotine

Paroxetine is a strong CYP2D6 inhibitor that may increase imipramine concentrations. Use caution and monitor.

Source: NLP:paroxetine

CYP1A2 substrate/inhibitor that may increase blood levels and/or toxicity of propranolol.

Source: NLP:propranolol hydrochloride

Possible interaction via competitive inhibition of CYP1A2 metabolism; caution advised.

Source: NLP:ropivacaine hydrochloride

Co-administration produced additive effects on decreased alertness and impaired psychomotor performance for 2 to 4 hours. Pharmacodynamic interaction with no alteration of either drug's pharmacokinetics.

Source: NLP:zaleplon

Additive effect of decreased alertness observed. No pharmacokinetic interaction except 20% decrease in imipramine peak levels.

Source: NLP:zolpidem tartrate

Additive effect of decreased alertness observed. 20% decrease in peak levels of imipramine with no other pharmacokinetic interaction.

Source: NLP:zolpidem tartrate sublingual